Savant Capital’s Iterum Therapeutics ITRM Stock Holding History

Savant Capital’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-926	Closed	-$3K	–	564
2022 Q2	$3K	Hold	926	–	–	﹤0.01%	557
2022 Q1	$5K	Hold	926	–	–	﹤0.01%	568
2021 Q4	$5K	Hold	926	–	–	﹤0.01%	562
2021 Q3	$8K	Hold	926	–	–	﹤0.01%	522
2021 Q2	$32K	Hold	926	–	–	﹤0.01%	497
2021 Q1	$20K	Buy	+926	New	+$22K	﹤0.01%	469

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Savant Capital's ITRM Position: Q3 2022 in Review

Savant Capital sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 926 shares — an estimated $3K sold.

Savant Capital first reported a position in ITRM in Q1 2021 and held it in 6 quarters. The position peaked at $32K in Q2 2021. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

Savant Capital reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
Savant Capital sold 926 Iterum Therapeutics shares in Q3 2022, an estimated $3K.
Savant Capital first reported a position in Iterum Therapeutics in Q1 2021 and held it in 6 quarters.
Savant Capital's Iterum Therapeutics position peaked at $32K in Q2 2021.
25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on Savant Capital's 13F filing for Q3 2022, filed 31 Oct 2022.